Posts

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on
AstraZeneca remains on track to achieve its $80 billion annual revenue target by 2030, despite recent trial setbacks involving its rare disease drug Ultomiris. Strong sales of cancer medicines and rare disease therapies, especially in oncology and respiratory and immunology, are driving revenue growth and offsetting the Ultomiris miss. Key oncology drugs such as Tagrisso, Imfinzi, Enhertu, and Calquence, along with rare disease products like Ultomiris and Strensiq, continue to deliver robust growth, supporting the long-term ambition. AstraZeneca reiterated its guidance for mid-to-high single-digit revenue growth in 2026 and highlighted over 20 high-value pipeline readouts expected in the next 18 months that could further boost revenue toward the $80 billion goal. Sources: AZ stays on track for $80B revenue goal as cancer meds ... AstraZeneca's rare disease drug misses main goal in late-stage trial What's Going on With AstraZeneca Stock Monday? - AstraZeneca (NYSE:...

MapLight shares sink on mixed Phase 2 schizophrenia readout

on

FDA Approves Otsuka's Tool SIMTRIYO

on

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Sarepta Taps Former AbbVie and Tessera CEO Michael Severino as New CEO to Lead Duchenne Drugmaker's Turnaround

on

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

FDA Adcomm Backs Popular Wellness Peptides Despite Staff Concerns

on

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

Summit Touts Updated HARMONi Data Showing Consistent Survival Benefit for Ivonescimab in Western NSCLC Patients

on

Bylvay Fails Phase 3 BOLD Trial in Biliary Atresia, Another Setback for Ipsen's Albireo Portfolio

on

Amgen Submits Extensive Data Package to FDA in Defense of Tavneos Approval

on

Emideltide narrowly voted down by FDA peptide advisory panel on Day 2

on

Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results

on